Penatalaksanan Pasien Adenokarsinoma Paru Mutasi Epidermal Growth Factor Receptor Ekson 21 dengan Metastasis Tulang
Abstract
Metastasis tulang adalah salah satu komplikasi dari kanker stage lanjut. Tulang merupakan metastasis yang paling sering dan paling awal dari kanker paru. Metastasis tulang berhubungan dengan kanker paru sebesar 30%-70% dan 20%-30% dari pasien kanker paru sudah memiliki metastasis tulang pada diagnosis awal. Kanker paru subtipe histologis adenokarsinoma secara signifikan berhubungan dengan risiko lebih tinggi untuk berkembang menjadi metastasis tulang. Metastasis tulang merupakan indikasi prognosis yang buruk bagi pasien kanker paru karena angka ketahanan hidupnya rata-rata kurang dari 6 bulan setelah diagnosis metastasis ditegakkan. Kasus ini memamparkan pasien perempuan usia 48 tahun dengan adenokarsinoma paru kanan T4N3M1c (pleura, tulang) stage IVB PS ECOG 1 dan diberikan tatalaksana kemoterapi dengan thyrosine kinase inhibitor (TKI) yaitu gefitinib 1x 250 mg setiap hari dan dilakukan pembedahan dekompresi stabilisasi pada tulang belakang.
Keywords
References
Rajabto W, Angkasa YK. Mutasi EGFR sebagai Faktor Prediktif Respons Pengobatan terhadap TKI ( Tyrosine Kinase Inhibitor ) pada Non-Small Cell Lung Cancer Stadium 4 : Sebuah Laporan Kasus. J Penyakit Dalam Indones. 2021;8(1):43–5.
Zhou Y, Yu QF, Peng AF, Tong WL, Liu JM, Liu ZL. The risk factors of bone metastases in patients with lung cancer. Sci Rep. 2017;7(1):1–6.
Cho YJ, Cho YM, Kim SH, Shin KH, Jung ST, Kim HS. Clinical analysis of patients with skeletal metastasis of lung cancer. BMC Cancer. 2019;19(1):1–10.
Wu S, Pan Y, Mao Y, Chen Y, He Y. Current progress and mechanisms of bone metastasis in lung cancer: A narrative review. Transl Lung Cancer Res. 2021;10(1):439–51.
Jusuf A. Pengobatan Kanker Paru. 1st ed. Jusuf A, editor. Jakarta: Departemen Pulmonologi & Kedokteran Respirasi FKUI; 2019. 57–70 p.
Saito S, Espinoza-Mercado F, Liu H, Sata N, Cui X, Soukiasian HJ. Current status of research and treatment for non-small cell lung cancer in never-smoking females. Cancer Biol Ther. 2017;18(6):359–68.
Dubin S, Griffin D. Lung cancer in non-smokers. Sci Med. 2020;117(4):375–84.
Gaughan EM, Cryer SK, Yeap BY, Jackman DM, Costa DB. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations. Lung Cancer. 2013;79(3):193–7.
Shi Y, Au JSK, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–62.
Nan X, Xie C, Yu X, Liu J. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget. 2017;8(43):112–26.
Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, et al. Treatment of uncommon EGFR mutations in non-small cell lung cancer: New evidence and treatment. Transl Lung Cancer Res. 2019;8(3):302–16.
Xie T, Zou Z, Liu C, Zhu Y, Xu Z, Wang L, et al. Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer : A Network Meta-Analysis. Hindawi. 2021;8(1):210–25.
Krawczyk P, Kowalski DM, Ramlau R, Kalinka-Warzocha E, Winiarczyk K, Stencel K, et al. Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations. Oncol Lett. 2017;13(6):4433–44.
Yoon HY, Ryu JS, Sim YS, Kim D, Lee SY, Choi J, et al. Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study. PLoS One. 2020;15(2):1–14.
Patel N, Wu P, Zhang H. Comparison of gefitinib as first- and secondline therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation. Cancer Manag Res. 2017;9(1):243–8.
Sutiman N, Tan SW, Tan EH, Lim WT, Kanesvaran R, Ng QS, et al. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. J Thorac Oncol. 2017;12(3):529–38.
Oliveira MBDR, Souza LC, Sampayo EJG, Carvalho GS De, Mello FCDQ, Paschoal MEM. The Impact of Lung Carcinoma Histology on Frequency of Bone Metastases. Rev Bras Ortop. 2019;54(5):524–30.
Krzeszinski J, Wan Y. New therapeutic targets for cancer bone metastases. Trends Pharmacol Sci. 2015;36(6):360–73.
Gu H, Sun L, Dou Z, Kong C, Zu J, Xiao J, et al. Analysis of lung adenocarcinoma with bone metastasis: A case report. Transl Lung Cancer Res. 2020;9(2):389–92.
Chen X, Wang Z, Duan N, Zhu G, Schwarz EM, Chao X. Osteoblast-Osteoclast Interactions. Physiol Behav. 2018;59(2):99–107.
Lv M, Zhang X, Shen Y, Wang F, Yang J, Wang B, et al. Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors. Med (United States). 2017;96(17):211–9.
D’Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management. J Bone Oncol. 2019;15(2):101–12.
Brown JE, Wood SL, Confavreux C, Abe M, Weilbaecher K, Hadji P, et al. Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations. J Bone Oncol. 2021;29(1):126–32.
Liu J, Huang W, Zhou R, Jia S, Tang W, Luo Y, et al. Bisphosphonates in the treatment of patients with metastatic breast, lung, and prostate cancer a meta-analysis. Medicine (Baltimore). 2015;94(46):1–4.
Feng C, Liu X, Li X, Guo F, Huang C, Qin Q, et al. Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations. Oncol Rep. 2016;35(6):3460–70.
Huang CY, Wang L, Feng CJ, Yu P, Cai XH, Yao WX, et al. Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study. Oncotarget. 2016;7(41):66480–90.
Zhang G, Gong H, Xu H. Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases. Hindawi. 2021;21(2):1–6.
De Castro J, García R, Garrido P, Isla D, Massuti B, Blanca B, et al. Therapeutic potential of denosumab in patients with lung cancer: Beyond prevention of skeletal complications. Clin Lung Cancer. 2015;16(6):431–46.
Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, et al. Bone metastases: An overview. Oncol Rev. 2017;11(1):121–31.
Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: Subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7(12):1823–9.
Rafli R, Anissa M. Peningkatan kualitas hidup pasien kanker dengan metastasis tulang yang menjalani radiasi paliatif. Maj Kedokt Andalas. 2019;42(1):1–10.
DOI: 10.24815/jks.v22i2.25599
Refbacks
- There are currently no refbacks.